2,2’-磺酰基双(3,4,6-三氯苯酚) | 1638-41-1

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2,2’-磺酰基双(3,4,6-三氯苯酚)
• 英文名称: p38 map kinase inhibitor IV
• 英文别名: 3,4,6-trichloro-2-(2,3,5-trichloro-6-hydroxyphenyl)sulfonylphenol
• CAS: 1638-41-1
• 化学式: C₁₂H₄Cl₆O₄S
• 分子量: 456.945
• InChiKey: AKUKHICVNCCQHN-UHFFFAOYSA-N

物化性质

• 熔点：
  244-245 °C(Solv: ethyl acetate (141-78-6))
• 沸点：
  590.0±50.0 °C(Predicted)
• 密度：
  1.854±0.06 g/cm3(Predicted)
• 溶解度：
  DMSO：可溶5mg/mL，澄清（加热）

计算性质

• 辛醇/水分配系数(LogP)：
  6.9
• 重原子数：
  23
• 可旋转键数：
  2
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  83
• 氢给体数：
  2
• 氢受体数：
  4

安全信息

• 海关编码：
  2908999090

文献信息

• P38 MAPK INHIBITOR-CONTAINING MEDIUM AND METHOD FOR OSTEOGENIC DIFFERENTIATION
  申请人：Tampereen Yliopisto

  公开号：EP2834349B1

  公开（公告）日：2016-04-20
• METHODS FOR PROMOTING CELL REPROGRAMMING
  申请人：Rana Tariq M.

  公开号：US20130064799A1

  公开（公告）日：2013-03-14

  The present invention is based on the seminal discovery that several kinases play important roles in barrier pathways in somatic cell reprogramming. The present invention provides that modulating expression or activity of these kinases can significantly promote or enhance cell reprogramming efficiency. Key kinases are identified and key regulation networks involving such kinases are also identified that may be advantageously targeted to significantly increase reprogramming efficiency as well as direct differentiation of induced pluripotent stem (iPS) cells.
• COMBINATION THERAPIES FOR MALARIA
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160151379A1

  公开（公告）日：2016-06-02

  The present disclosure provides methods for treating or preventing malaria by administration of a protein kinase inhibitor and optionally one or both of a further protein kinase inhibitor and an antimalarial drug to a mammalian subject infected with or at risk of exposure to Plasmodium sp. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in mosquitoes feeding on recipients of the regimens. Additionally, the present disclosure provides methods for screening candidate antimalarial agents.
• THERAPIES FOR DISEASES CAUSED BY ARTHROPOD-BORNE PARASITES
  申请人：THE REGENTS OF THE UNIVERSITY OF CALIFORNIA

  公开号：US20160151380A1

  公开（公告）日：2016-06-02

  The present disclosure provides methods for treating or preventing diseases caused by arthropod-borne parasites by administration of a protein kinase inhibitor to a mammalian subject infected with or at risk of exposure to an arthropod-borne parasite. In some aspects, the therapeutic and prophylactic regimens of the present disclosure are effective in reducing parasite development in arthropods feeding on recipients of the regimens. Additionally, the present disclosure provides methods for screening candidate anti-parasitic agents.
• TKI PERMEABILITY ENHANCERS
  申请人：City of Hope

  公开号：US20190083650A1

  公开（公告）日：2019-03-21

  Provided herein are, inter alia, methods useful for delivering nucleic acids and kinase inhibitors to a cell. The methods provided herein include the delivery of therapeutic nucleic acids to cancer cells by contacting a cancer cell with a kinase inhibitor and a therapeutic nucleic acid. The methods provided herein are therefore, inter alia, useful for the treatment of cancer.